Literature DB >> 6628515

Effects of prenalterol on cardiac performance and transmural myocardial perfusion in patients with chronic renal failure.

T Pedersen, K Cleemann-Rasmussen, I Brynjolf, H Ording, P E Nielsen, K Rasmussen.   

Abstract

The acute haemodynamic effects of the beta-adrenoreceptor agonist, prenalterol, were studied in six patients with chronic end-stage renal failure. Prenalterol 0.8 mg, 1.6 mg, and 3.2 mg was administered i.v. as a bolus, and after the last dose the selective adrenergic beta-1-receptor antagonist metoprolol was administered i.v. in doses of 5 and 10 mg. The haemodynamic effects of the drugs were investigated using impedance cardiography and radionuclide angiocardiography. The main haemodynamic effects were a dose-related chronotropic effect, demonstrated by an increase in heart rate (26%; less than 0.05), and an inotropic effect, shown by an increase in stroke volume index (20%; p less than 0.05) and left ventricular ejection time (12%; p less than 0.05); the cardiac index was increased by 47% (p less than 0.05). Transmural myocardial perfusion (DPTI/SPTI ratio) was decreased by 22% (p less than 0.05) after prenalterol. It is concluded that prenalterol has positive inotropic and chronotropic effects in patients with chronic renal failure, that the improvement in left ventricular performance is at the expense of a decreased transmural myocardial perfusion, and that metoprolol is a specific antidote.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628515     DOI: 10.1007/bf01037935

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Human pharmacology studies with a new, orally active stimulant of cardiac adrenergic beta-receptors.

Authors:  M Knaus; B Pfister; U C Dubach; P R Imhof
Journal:  Am Heart J       Date:  1978-05       Impact factor: 4.749

Review 2.  Determinants and prediction of transmural myocardial perfusion.

Authors:  J I Hoffman
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690

3.  The specific resistance of blood at body temperature.

Authors:  L A Geddes; C Sadler
Journal:  Med Biol Eng       Date:  1973-05

4.  Development and evaluation of an impedance cardiac output system.

Authors:  W G Kubicek; J N Karnegis; R P Patterson; D A Witsoe; R H Mattson
Journal:  Aerosp Med       Date:  1966-12

5.  Effect of parathyroidectomy on left-ventricular function in haemodialysis patients.

Authors:  T Drüeke; M Fauchet; J Fleury; P Lesourd; Y Toure; C Le Pailleur; P de Vernejoul; J Crosnier
Journal:  Lancet       Date:  1980-01-19       Impact factor: 79.321

Review 6.  Radionuclide assessment of left and right ventricular performance.

Authors:  H J Berger; A Gottschalk; B L Zaret
Journal:  Radiol Clin North Am       Date:  1980-12       Impact factor: 2.303

7.  Cardiovascular effects of prenalterol (H133/22) in normal man.

Authors:  D H Scott; G R Arthur; R N Boyes; D B Scott
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

8.  Haemodynamic effects of a new beta 1-receptor agonist in acute myocardial infarction. A useful antidote to unwanted cardiac effects of beta-blocking agents.

Authors:  R Ariniego; F Waagstein; B Mombay; A Hjalmarson
Journal:  Br Heart J       Date:  1979-08

9.  Immediate haemodynamic effects of prenalterol, a new adrenergic beta-1-receptor agonist, in healthy volunteers.

Authors:  T L Svendsen; O J Hartling; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

10.  Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta 1-adrenoceptor agonist, prenalterol, in man.

Authors:  O Rönn; E Fellenius; C Graffner; G Johnsson; P Lundborg; L Svensson
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

View more
  1 in total

1.  Dose-response relationship in normal subjects of prenalterol, a beta-adrenergic agonist with positive inotropic and resistance lowering effects.

Authors:  S Rasmussen; P F Høilund-Carlsen; B Hesse; O J Hartling; J Fabricius; H Dige-Petersen; J Giese
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.